Sistema de Salut de Catalunya
Institut Català de la Salut
[De Mattos-Arruda L] Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK. University of Cambridge, Cambridge, UK. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sammut SJ, Ross EM] Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK. University of Cambridge, Cambridge, UK. [Bashford-Rogers R] Department of Medicine, University of Cambridge, Cambridge, UK. [Greenstein E] Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. [Markus H] Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, USA. Mayo Clinic Center for Individualized Medicine, Scottsdale, USA. [Mayor R, Arias A] Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. [Ciriaco N] Servei d’Anatomia Patològica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Martinez-Saez E] Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Peg V, Ramon Y Cajal S] Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Cortes J] Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Ramon y Cajal Hospital, Madrid, Spain. [Seoane J] Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2019-08-08T06:29:26Z
2019-08-08T06:29:26Z
2019-05-28
TCR repertoire; Breast cancer; Clade mutations
Repertori TCR; Càncer de mama; Mutacions clade
Repertorio TCR; Cáncer de mama; Mutaciones clado
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. The integrated genomic and immune landscapes show that metastases propagate and evolve as communities of clones, reveal their predicted neo-antigen landscapes, and show that they can accumulate HLA loss of heterozygosity (LOH). The data further identify variable tumor microenvironments and reveal, through analyses of T cell receptor repertoires, that adaptive immune responses appear to co-evolve with the metastatic genomes. These findings reveal in fine detail the landscapes of lethal metastatic breast cancer.
Article
Published version
English
Mama - Càncer - Aspectes genètics; Mama - Càncer - Aspectes immunològics; Metàstasi; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; Other subheadings::Other subheadings::Other subheadings::/genetics; Other subheadings::Other subheadings::Other subheadings::/immunology; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica; Otros calificadores::Otros calificadores::Otros calificadores::/genética; Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
Elsevier
Cell Reports;27(9)
https://www.sciencedirect.com/science/article/pii/S2211124719305789?via%3Dihub
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
Articles científics - VHIR [1665]
